§
Luxuse
Patent Intelligence
Sign In
Patent US5856462A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5856462A Expired / Lapsed US ⏱️ 0.0 years remaining

Oligonucleotides having modified CpG dinucleosides

Assignee: Aceragen Inc
•
Filing: 1996-09-10
•
Granted: 1999-01-05
•
Expires: 2016-09-10
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to modified oligonucleotides that are useful for studies of gene expression and for the antisense therapeutic approach. The invention provides modified oligonucleotides that inhibit gene expression and that produce fewer side effects than conventional phosphorothioate oligonucleotides. In particular, the invention provides modified CpG-containing oligonucleotides that result in reduced splenomegaly and platelet depletion when administered to a mammal, relative to conventional CpG-containing phosphorothioate oligonucleotides. The invention further provides methods for using such oligonucleotides to modulate gene expression in vivo, including such use for therapeutic treatment of diseases caused by aberrant gene expression.

Inventors

  • 👤 Sudhir Agrawal

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 04:45
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; A; A61; A61K; A61K38/00; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/311; C12N2310/312; C12N2310/314; C12N2310/315; C12N2310/32; C12N2310/321; C12N2310/33; C12N2310/334; C12N2310/3341

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 67 words
A oligonucleotide for inhibiting specific gene expression with reduced side effects, the composition comprising a modified CpG-containing phosphorothioate oligonucleotide that is complementary to a portion of a genomic region or gene for which inhibition of expression is desired, or to RNA transcribed from such a gene, wherein the modified CpG is selected from alkylphosphonate CpG, inverted CpG, stereospecific phosphorotioate CpG, phosphotriester CpG, phosphoramidate CpG and 2'-5' CpG.
Claim 2
Dependent Claim 67 words
A oligonucleotide for inhibiting specific gene expression with reduced side effects, the composition comprising a modified CpG-containing phosphorothioate oligonucleotide that is complementary to a portion of a genomic region or gene for which inhibition of expression is desired, or to RNA transcribed from such a gene, wherein the modified CpG is selected from alkylphosphonate CpG, inverted CpG, stereospecific phosphorotioate CpG, phosphotriester CpG, phosphoramidate CpG and 2'-5' CpG.
Claim 3
Dependent Claim 14 words
The oligonucleotide according to claim 1, wherein the modified CpG is a alkylphosphonate CpG.
Claim 4
Dependent Claim 14 words
The oligonucleotide according to claim 1, wherein the modified CpG is an inverted CpG.
Claim 5
Dependent Claim 15 words
The oligonucleotide according to claim 1, wherein the modified CpG is a stereospecific phosphorothioate CpG.
Claim 6
Dependent Claim 14 words
The oligonucleotide according to claim 1, wherein the modified CpG is a phosphotriester CpG.
Claim 7
Dependent Claim 14 words
The oligonucleotide according to claim 1, wherein the modified CpG is a phosphoramidate CpG.
Claim 8
Dependent Claim 14 words
The oligonucleotide according to claim 1, wherein the modified CpG is a 2'-5' CpG.

References Cited (Backward Citations)

US4806463A Cited
US5194428A Cited
US5149797A Cited
WO1993013749A2 Cited
WO1994002498A1 Cited
WO1994026877A1 Cited
WO1995009236A1 Cited
WO1996002555A1 Cited
WO1996019572A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2002-01-04 2002-07-06 2003-01-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2006-01-04 2006-07-06 2007-01-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2010-01-04 2010-07-06 2011-01-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag